Should I Buy ESTA? ESTA 2026 Analysis

Should You Buy Establishment Labs Holdings Inc (ESTA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

70.990

1 Day change

1.07%

52 Week Range

83.310

Analysis Updated At

2026/05/01

Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

ESTA is not a clean buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has strong momentum and a bullish technical setup, but the latest analyst target cuts, insider/hedge fund selling, and mixed earnings quality make the risk/reward less attractive at this exact level. My direct view is to hold off on adding aggressively today and wait for a better entry, even though the recent move and SwingMax signal show the stock can continue higher.

Technical Analysis

The chart is constructive: MACD histogram is positive and expanding, RSI at 64.2 shows bullish momentum without being overbought, and the moving averages are aligned bullishly (SMA 5 > SMA 20 > SMA 200). Price at 69.05 is above pivot 65.21 and near resistance at 69.97, so the stock is trading close to a short-term ceiling after a strong 9.93% regular-session gain. Near-term trend remains up, but upside from here looks more dependent on a breakout above 69.97.

Options Data

Bearish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options sentiment is mixed to slightly cautious. Open interest put-call ratio of 1.06 leans slightly bearish/hedged, while the very low volume put-call ratio of 0.01 suggests heavy call activity today. Implied volatility at 79.33 is elevated, with IV percentile 78.09, showing traders expect sizable movement. Overall, options positioning suggests optimism for upside, but with meaningful hedging and event risk around earnings.

Technical Summary

Sell

Buy

Positive Catalysts

- Revenue in Q4 2025 grew 45.16% YoY, showing very strong top-line momentum.
- Gross margin improved to 70.46%, which supports better operating leverage over time.
- The company secured a $300 million senior secured term loan from Oaktree, extending debt maturity to 2031, which reduces near-term refinancing pressure.
- Mizuho and several other analysts remain constructive, with targets as high as $100 and a view that recent weakness was overdone.
- SwingMax issued an entry signal on 2026-04-06, and the stock is up 16.68% since then, confirming a meaningful bullish swing.

Neutral/Negative Catalysts

- Citi cut its price target to $65 from $74 and kept a Neutral rating, which is below the current price.
- Hedge funds are selling, with selling up 348.78% over the last quarter.
- Insiders are selling, with selling up 225.41% over the last month.
- Net income and EPS were still negative in the latest quarter, despite revenue growth.
- Earnings are scheduled for 2026-05-06 pre-market, so near-term volatility is likely elevated.

Financial Performance

In Q4 2025, Establishment Labs posted strong revenue growth of 45.16% YoY to $64.6M, which is the main positive in the latest quarter. Gross margin also improved to 70.46%, indicating healthier unit economics. However, profitability remains weak: net income was -$2.6M and EPS was -$0.09, both worse year over year. This was a growth quarter, but not yet a clean earnings-quality turnaround.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst sentiment is mixed but still more positive than negative overall. Recent raises from Canaccord, Mizuho, TD Cowen, and Stephens were constructive after Q4 results, with price targets ranging from $90 to $100 and generally Buy/Outperform/Overweight views. However, Citi recently lowered its target to $65 and kept Neutral, which is below the current share price and signals limited near-term upside from a more cautious Wall Street camp. Wall Street’s pro case is the multi-year growth runway and margin improvement; the con case is valuation uncertainty, ongoing losses, and the stock already running ahead of some neutral targets.

8 Analyst Rating

Wall Street analysts forecast ESTA stock price to rise

7 Buy

1 Hold

0 Sell

Strong Buy

Current: 70.240

Low

Averages

82.88

High

Current: 70.240

Low

Averages

82.88

High

Citi

Joanne Wuensch

Neutral

downgrade

$74 -> $65

AI Analysis

2026-04-07

Reason

Citi

Joanne Wuensch

Price Target

$74 -> $65

AI Analysis

2026-04-07

downgrade

Neutral

Reason

Citi analyst Joanne Wuensch lowered the firm's price target on Establishment Labs to $65 from $74 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology group as part of a Q1 preview. The "walls of worry are high" into the earnings reports with the sector undergoing significant multiple compression, the analyst tells investors in a research note. Citi removed iRhythm and Medtronic as top picks. The firm's top picks are now Edwards Lifesciences and Intuitive Surgical.

Mizuho

Outperform

maintain

$100

2026-03-24

Reason

Mizuho

Price Target

$100

2026-03-24

maintain

Outperform

Reason

Mizuho says Establishment Labs shares are down 28% since February 28, the first day of the U.S.-Iran conflict, which is "unwarranted and overdone." Establishment has pulled back on concerns that rising oil prices will pressure the company's margins and consumer demand, the analyst tells investors in a research note. Mizuho adds that the stock has been weak more recently on "unsubstantiated evidence" of a short report and insider selling from former CEO Jaun Jose Chacon. The firm believes the macro concerns are "well overdone" considering Establishment purchases silicone under forward contracts while demand at the consumer level, particularly for Preserve, "remains robust." Further, no short report was published, and insider selling is part of a planned previously disclosed 10b5-1 plan, contends Mizuho. As such, it views the stock's current weakness as an "attractive entry point into a best-in-class growth story." Mizuho has an Outperform rating on Establishment Labs with a $100 price target. The stock is down 6% to $56.29 in afternoon trading.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ESTA

Unlock Now

ESTA Should I Buy

ESTA Should I Buy

Should You Buy Establishment Labs Holdings Inc (ESTA) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch